PE20211463A1 - Compuestos de aminoacidos y metodos de uso - Google Patents
Compuestos de aminoacidos y metodos de usoInfo
- Publication number
- PE20211463A1 PE20211463A1 PE2021000461A PE2021000461A PE20211463A1 PE 20211463 A1 PE20211463 A1 PE 20211463A1 PE 2021000461 A PE2021000461 A PE 2021000461A PE 2021000461 A PE2021000461 A PE 2021000461A PE 20211463 A1 PE20211463 A1 PE 20211463A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- cycloalkyl
- alkyl
- alkylene
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invencion se refiere a compuestos de la formula (I), donde: R1 es 5,6,7,8-tetrahidro-1,8-naftiridin-2-ilo opcionalmente sustituido por R4, 1,2,3,4- tetrahidro-1,8-naftiridin-2-ilo opcionalmente sustituido por R4, 6-aminopiridin-2-ilo opcionalmente sustituido por R4 o (piridin-2-il)amino opcionalmente sustituido por R4 ; G es -C(O)R2 o R3; R2 es C1-C6 alquilo opcionalmente sustituido por R2a, C3-C8 cicloalquilo opcionalmente sustituido por R2b, entre otros; R3 es C1-C6 alquilo opcionalmente sustituido por R3a, C3-C8 cicloalquilo opcionalmente sustituido por R3b, entre tros; L1 es C2-C4 alquileno opcionalmente sustituido por R4; L2 es un enlace o C1-C3 alquileno opcionalmente sustituido por R4; L3 es C2-C4 alquileno opcionalmente sustituido por R4; Y es un enlace o C3-C5 cicloalquileno opcionalmente sustituido por Ya; cada R2a, R2b, 3a, R3b e Ya es oxo o R4; cada R4 es deuterio, halogeno, C1-C6 alquilo, C2-C6 alquenilo, C2- C6 alquinilo, C3-C8 cicloalquilo, heterociclilo de 3 a 12 miembros, C6-C14 arilo, entre otros; Tambien esta referida a composiciones farmaceuticas. Dichos compuestos son inhibidores de una o ambas de la integrina alfaVbeta1 y la integrina alfaVbeta6, siendo utiles para tratar la fibrosis, tal como en esteatohepatitis no alcoholica (NASH), fibrosis pulmonar idiopatica (IPF) y neumonia intersticial inespecifica (NSIP).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| PCT/US2019/055252 WO2020076862A1 (en) | 2018-10-08 | 2019-10-08 | Amino acid compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211463A1 true PE20211463A1 (es) | 2021-08-05 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000461A PE20211463A1 (es) | 2018-10-08 | 2019-10-08 | Compuestos de aminoacidos y metodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11180494B2 (es) |
| EP (1) | EP3863711A4 (es) |
| JP (1) | JP2022508657A (es) |
| KR (1) | KR20210101205A (es) |
| CN (1) | CN113195053A (es) |
| AU (1) | AU2019358041A1 (es) |
| BR (1) | BR112021006620A2 (es) |
| CA (1) | CA3115643A1 (es) |
| CL (2) | CL2021000863A1 (es) |
| CO (1) | CO2021004279A2 (es) |
| CR (1) | CR20210224A (es) |
| CU (1) | CU24690B1 (es) |
| DO (1) | DOP2021000054A (es) |
| EA (1) | EA202190967A1 (es) |
| EC (1) | ECSP21032717A (es) |
| IL (1) | IL282026A (es) |
| JO (1) | JOP20210056A1 (es) |
| MX (1) | MX2021004015A (es) |
| PE (1) | PE20211463A1 (es) |
| PH (1) | PH12021550784A1 (es) |
| SG (1) | SG11202103283RA (es) |
| TW (1) | TW202028179A (es) |
| WO (1) | WO2020076862A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
| MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| BR112020018064A2 (pt) | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
| IL279717B2 (en) | 2018-06-27 | 2024-05-01 | Pliant Therapeutics Inc | Amino acid compounds with non-branched linkers and methods of use |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| SG11202110889WA (en) | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| AU2021381516A1 (en) | 2020-11-19 | 2023-06-22 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| AR067329A1 (es) * | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファｖベータ１インテグリン阻害剤及び使用方法 |
| EP3275883B1 (en) | 2015-03-25 | 2021-06-02 | FUJIFILM Corporation | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same |
| EP3481814B1 (en) | 2016-07-05 | 2022-04-27 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
| AR110139A1 (es) | 2016-11-08 | 2019-02-27 | Bristol Myers Squibb Co | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
| MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| BR112020018064A2 (pt) | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
| TWI741268B (zh) | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑 |
| IL279717B2 (en) | 2018-06-27 | 2024-05-01 | Pliant Therapeutics Inc | Amino acid compounds with non-branched linkers and methods of use |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
| EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| SG11202110889WA (en) | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
| MX2022013753A (es) | 2020-05-07 | 2023-01-30 | Pliant Therapeutics Inc | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
- 2019-10-08 JP JP2021544112A patent/JP2022508657A/ja active Pending
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en active Pending
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en active Pending
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en active Application Filing
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053A/zh active Pending
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021004279A2 (es) | 2021-04-30 |
| CL2023001331A1 (es) | 2023-10-20 |
| CA3115643A1 (en) | 2020-04-16 |
| KR20210101205A (ko) | 2021-08-18 |
| JP2022508657A (ja) | 2022-01-19 |
| SG11202103283RA (en) | 2021-04-29 |
| BR112021006620A2 (pt) | 2021-07-06 |
| EA202190967A1 (ru) | 2021-09-17 |
| MX2021004015A (es) | 2021-06-23 |
| EP3863711A4 (en) | 2022-07-06 |
| CU20210027A7 (es) | 2021-11-04 |
| US20200109141A1 (en) | 2020-04-09 |
| US11952376B2 (en) | 2024-04-09 |
| WO2020076862A1 (en) | 2020-04-16 |
| DOP2021000054A (es) | 2021-08-31 |
| IL282026A (en) | 2021-05-31 |
| CN113195053A (zh) | 2021-07-30 |
| US20220144829A1 (en) | 2022-05-12 |
| CL2021000863A1 (es) | 2021-09-10 |
| CU24690B1 (es) | 2023-12-07 |
| EP3863711A1 (en) | 2021-08-18 |
| ECSP21032717A (es) | 2021-06-30 |
| CR20210224A (es) | 2021-06-08 |
| AU2019358041A1 (en) | 2021-05-20 |
| TW202028179A (zh) | 2020-08-01 |
| US11180494B2 (en) | 2021-11-23 |
| PH12021550784A1 (en) | 2021-10-25 |
| JOP20210056A1 (ar) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211463A1 (es) | Compuestos de aminoacidos y metodos de uso | |
| PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
| ECSP20063227A (es) | Compuestos de aminoácidos y métodos de uso | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| PE20210137A1 (es) | Compuestos de aminoacidos con ligadores no ramificados y metodos de uso | |
| ECSP18032223A (es) | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO DE USO | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| UY36201A (es) | Herbicidas de piperidinona | |
| CO2017012518A2 (es) | Derivados de 2-(feniloxi o feniltio) pirimidina como herbicidas | |
| PH12020550921A1 (en) | Cap-dependent endonuclease inhibitors | |
| BR112016028942A2 (pt) | método para preparar uma composição estável com perfume | |
| CR20160548A (es) | Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1 | |
| PE20142340A1 (es) | Inhibidores de bromodominios | |
| CL2019003032A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. | |
| AR051315A1 (es) | Pirimidinas 5-sustituidas inhibidoras del vih | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| CY1123527T1 (el) | Αντιφυματικος παραγοντας | |
| BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
| PE20190151A1 (es) | Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3 | |
| PE20180696A1 (es) | Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas | |
| CL2018003793A1 (es) | Reducción de deriva de pulverización. |